The company has seen promising activity for the drug in KRAS-mutated metastatic colorectal cancer, and biomarker-defined patient subgroups with castration-resistant prostate cancer and AML.
A case series in partnership with My Gene Counsel to highlight the challenges genetics professionals and oncologists are grappling with as genetic testing is increasingly used in patient care.
The findings should spur cancer centers to review testing rates and address barriers, said experts from Hackensack University, Cota Healthcare, and Guardant Health.
Benefit was seen for patients with high TMB on Keytruda, with ERBB2 amplifications on Perjeta and Herceptin, and with BRAF mutations on Cotellic plus Zelboraf.
A case series in partnership with My Gene Counsel to highlight the challenges genetics professionals and oncologists are grappling with as genetic testing is increasingly used in patient care.
Five Prime Therapeutics provided an update on the development of bemarituzumab and FPA150, and Gritstone Oncology discussed plans for its personalized immunotherapies.
